About Us

Adlyfe Inc. was established early in 2003 to develop novel technologies for testing for early targets of amyloid diseases. Adlyfe is developing a novel test for the detection and amplification of amyloid proteins as early biomarkers of fatal brain diseases.

Our Technology:

Our novel technology is based on the synthesis of small peptide ligands (Pronucleon^TM ligands) which are amino acid sequence matched to target amyloids of interest. Ligand sequences are selected based on regions of the target protein known to undergo conformational changes associated with amyloid formation. Ligand sequence selection is the basis for our assay specificity. The interaction of the target amyloid protein with our proprietary ligands induces the ligands to undergo a conformational change that transduces a fluorescent signal. Further amplification of the signal is generated as additional ligands are nucleated to undergo conformational changes. This is the basis for our sensitivity and ability to detect very low amyloid protein levels before symptoms occur.

Ann Hanham, PhD - Chief Executive Officer
Ann Hanham is a Managing Director and General Partner with Burrill & Company, a venture firm that invests in life science companies whose technologies and products are innovative in areas of huge unmet need.  Ann has strong clinical, regulatory and financial experience in the Biotech industry having been a co-founder and Vice President of Clinical & Regulatory Affairs at InterMune Pharmaceuticals, and an investment member of the Burrill team for over 10 years (Burrill & Company is an active investor in Adlyfe). She is currently a member of the Board of Directors of Adlyfe, Aerovance, Cardiokine (observer), Endocyte, Logical Therapeutics (observer), SCYNEXIS, Taiwan Liposome Company,and Waterstone.

Giora Feuerstein, MD, MSc, FAHA – Chief Scientific Officer, VP Translational Medicine
Giora Feuerstein has recently retired from Pfizer Inc to assume the position of Chief Scientific officer and VP Translational medicine at AdLyfe. In his recent position at Wyeth Research/Pfizer, Dr Feuerstein held the position of AVP and head, Discovery Translational Medicine, a department he built since he joined Wyeth in 2005. Dr Feuerstein developed a novel Translational medicine discipline and the Translational Medicine consortia TMRC, an Academia-Pharma-Government collaboration in Scotland. Along his 23 years in major Pharmaceutical Industry, Dr Feuerstein led strategic business development, compound acquisition, technology development, and regulatory reviews/ interactions. Dr Feuerstein serves on editorial boards of prestigious scientific and technical journals and is the recipient of several national and international awards including the American Heart Association, Prix Galien Award for drug Discovery (enrasartan), Henry Ford Foundation and Wyeth, R&D President Award 2008. Giora has authored and co-authored over 400 papers in peer reviewed journals, edited 10 books and is the co-inventors of 12 patents.